Ketone Body β-Hydroxybutyric Acid Ameliorates Dopaminergic Neuron Injury Through Modulating Zinc Finger Protein 36/Acyl-CoA Synthetase Long-Chain Family Member Four Signaling Axis-Mediated Ferroptosis

Yu, Xin; Yang, Yunpeng; Zhang, Bo; Han, Guangyu; Jiang, Yu; Qian, Yu; Zhang, Lei

doi:10.1016/j.neuroscience.2022.11.018

Cited by 15 publications

(8 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 111 It has been suggested that β-hydroxybutyrate and the probiotic strain L. lactis MG1363-pMG36e-GLP-1 have the potential to modulate lipid peroxidation-driven ferroptosis by targeting ACSL4, thereby benefiting the treatment of PD. 112 , 113 Additionally, phospholipase iPLA2β (PLA2G6) was shown to inhibit ROS-induced ferroptosis by scavenging oxidized PUFAs tails in phospholipids, 114 , 115 and its inactivation or deficiency leads to PD-related motor deficits. 116 …”

Section: Discussionmentioning

confidence: 99%

“… 188 The first animal model of PD in which ferroptosis was found was induced by MPTP, and the toxicity of MPTP was inhibited by Fer-1, a specific ferroptosis inhibitor, as reported by multiple sources. 23 , 111 , 113 Liangqin Shi et al established a stable MPTP-induced monkey model of PD by adopting a long-term gradual regimen and demonstrated that CQ can help to reduce iron concentration and ROS levels in the SN, block p53-mediated cellular ferroptosis, and improve motor and nonmotor deficits in PD monkeys. 189 In addition, LUHMES, SH-SY5Y, and PC12 cells also experienced ferroptosis induced by MPP + .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mapping the Research of Ferroptosis in Parkinson’s Disease from 2013 to 2023: A Scientometric Review

Chen,

Wu,

et al. 2024

DDDT

View full text Add to dashboard Cite

Methods Related studies on PD and ferroptosis were searched in Web of Science Core Collection (WOSCC) from inception to 2023. VOSviewer, CiteSpace, RStudio, and Scimago Graphica were employed as bibliometric analysis tools to generate network maps about the collaborations between authors, countries, and institutions and to visualize the co-occurrence and trends of co-cited references and keywords. Results A total of 160 original articles and reviews related to PD and ferroptosis were retrieved, produced by from 958 authors from 162 institutions. Devos David was the most prolific author, with 9 articles. China and the University of Melbourne had leading positions in publication volume with 84 and 12 publications, respectively. Current hot topics focus on excavating potential new targets for treating PD based on ferroptosis by gaining insight into specific molecular mechanisms, including iron metabolism disorders, lipid peroxidation, and imbalanced antioxidant regulation. Clinical studies aimed at treating PD by targeting ferroptosis remain in their preliminary stages. Conclusion A continued increase was shown in the literature within the related field over the past decade. The current study suggested active collaborations among authors, countries, and institutions. Research into the pathogenesis and treatment of PD based on ferroptosis has remained a prominent topic in the field in recent years, indicating that ferroptosis-targeted therapy is a potential approach to halting the progression of PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Mapping the Research of Ferroptosis in Parkinson’s Disease from 2013 to 2023: A Scientometric Review

Chen,

Wu,

et al. 2024

DDDT

View full text Add to dashboard Cite

show abstract

“…An increasing number of emerging compounds targeting have been found to exert their therapeutic efficacy through the ferroptosis cell defense system. Compounds may exert to alleviate the PD syndrome by activating GPX4-mediated ferroptosis cellular defenses system [ 27 ], such as (-)-Clausen amide [ 139 ], β-Hydroxybutyric acid [ 140 ], Quercetin [ 141 ], Dl-3-n-butylphthalide [ 142 ], thonningianin A [ 143 ], paeoniflorin [ 144 ], α-Lipoic acid [ 145 ], deferoxamine [ 146 ], ferrostatin-1 [ 95 ], and idebenone [ 147 ]. Compounds such as apoferritin attenuate PD by modulating FSP1-mediated ferroptosis cellular defenses system [ 97 ].…”

Section: Discussionmentioning

confidence: 99%

The Role of Cellular Defense Systems of Ferroptosis in Parkinson’s Disease and Alzheimer’s Disease

Chu,

Li,

Sun

et al. 2023

IJMS

View full text Add to dashboard Cite

Parkinson’s disease (PD) and Alzheimer’s disease (AD) are the most common rapidly developing neurodegenerative diseases that lead to serious health and socio-economic consequences. Ferroptosis is a non-apoptotic form of cell death; there is growing evidence to support the notion that ferroptosis is involved in a variety of pathophysiological contexts, and there is increasing interest in the role of ferroptosis in PD and AD. Simultaneously, cells may have evolved four defense systems to counteract the toxic effects of ferroptosis occasioned by lipid peroxidation. This review, which focuses on the analysis of ferroptosis in the PD and AD context, outlines four cellular defense systems against ferroptosis and how each of them is involved in PD and AD.

show abstract

“…Quercetin, [ 350 ] Dl‐3‐n‐butylphthalide, [ 109 , 351 ] β ‐hydroxybutyric acid, [ 352 ] thonningianin A, [ 112 ] GW501516 (a specific PPAR δ agonist), [ 111 ] hinokitiol, [ 113 ] paeoniflorin, [ 125 ] α ‐Lipoicacid, [ 114 ] iron chelator deferoxamine (DFO), [ 353 ] SK4/DFO, [ 354 ] clioquinol, [ 115 ] apoferritin, [ 126 ] ferrostatin‐1, [ 110 , 355 ] SK4/DFO, [ 354 ] and idebenone [ 356 ] alleviate PD through inhibiting ferroptosis (Table 1 ).…”

Section: Pharmacological Inhibition Of Ferroptosis To Treat Nds and S...mentioning

confidence: 99%

Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and Strokes

Wang

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Emerging evidence suggests that ferroptosis, a unique regulated cell death modality that is morphologically and mechanistically different from other forms of cell death, plays a vital role in the pathophysiological process of neurodegenerative diseases, and strokes. Accumulating evidence supports ferroptosis as a critical factor of neurodegenerative diseases and strokes, and pharmacological inhibition of ferroptosis as a therapeutic target for these diseases. In this review article, the core mechanisms of ferroptosis are overviewed and the roles of ferroptosis in neurodegenerative diseases and strokes are described. Finally, the emerging findings in treating neurodegenerative diseases and strokes through pharmacological inhibition of ferroptosis are described. This review demonstrates that pharmacological inhibition of ferroptosis by bioactive small‐molecule compounds (ferroptosis inhibitors) could be effective for treatments of these diseases, and highlights a potential promising therapeutic avenue that could be used to prevent neurodegenerative diseases and strokes. This review article will shed light on developing novel therapeutic regimens by pharmacological inhibition of ferroptosis to slow down the progression of these diseases in the future.

show abstract

Ketone Body β-Hydroxybutyric Acid Ameliorates Dopaminergic Neuron Injury Through Modulating Zinc Finger Protein 36/Acyl-CoA Synthetase Long-Chain Family Member Four Signaling Axis-Mediated Ferroptosis

Cited by 15 publications

References 46 publications

Mapping the Research of Ferroptosis in Parkinson’s Disease from 2013 to 2023: A Scientometric Review

Mapping the Research of Ferroptosis in Parkinson’s Disease from 2013 to 2023: A Scientometric Review

The Role of Cellular Defense Systems of Ferroptosis in Parkinson’s Disease and Alzheimer’s Disease

Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and Strokes

Contact Info

Product

Resources

About